Prandoni Paolo
Department of Medicine, Vascular Medicine Unit, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
Adv Exp Med Biol. 2017;906:89-100. doi: 10.1007/5584_2016_108.
Once anticoagulation is stopped, the risk of recurrent venous thromboembolism (VTE) over years after a first episode is consistently around 30 %. This risk is higher in patients with unprovoked than in those with (transient) provoked VTE, and among the latter in patients with medical than in those with surgical risk factors. Baseline parameters that have been found to be related to the risk of recurrent VTE are the proximal location of deep vein thrombosis, obesity, old age, male sex and non-0 blood group, whereas the role of inherited thrombophilia is controversial. The persistence of residual vein thrombosis at ultrasound assessment has consistently been shown to increase the risk, as do persistently high values of D-dimer and the early development of the post-thrombotic syndrome. Strategies that incorporate the assessment of residual vein thrombosis and D-dimer have the potential to identify subjects in whom anticoagulation can be safely discontinued. Moreover, new opportunities are offered by a few anti-Xa and anti-IIa oral compounds, which are likely to induce fewer haemorrhagic complications than vitamin K antagonists while preserving the same effectiveness.
一旦停止抗凝治疗,首次发作后数年复发性静脉血栓栓塞症(VTE)的风险始终约为30%。无诱因VTE患者的这种风险高于有(短暂)诱因的VTE患者,而在后者中,有内科风险因素的患者高于有外科风险因素的患者。已发现与复发性VTE风险相关的基线参数包括深静脉血栓形成的近端部位、肥胖、老年、男性和非O血型,而遗传性易栓症的作用存在争议。超声评估时残余静脉血栓的持续存在一直被证明会增加风险,D - 二聚体持续高值和血栓后综合征的早期发展也是如此。纳入残余静脉血栓和D - 二聚体评估的策略有可能识别出可以安全停用抗凝治疗的患者。此外,一些抗Xa和抗IIa口服化合物提供了新的机会,它们可能比维生素K拮抗剂引起更少的出血并发症,同时保持相同的疗效。